Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

ABBV 2026 Q1

For the quarter ended March 31, 2026, AbbVie reported broad revenue growth led by immunology and neuroscience, while Humira and Imbruvica declines remained portfolio headwinds; management raised its full-year adjusted EPS guidance.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry.
  • Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology.
  • Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Risks that still need monitoring

  • Humira erosion

    Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition.

  • Oncology portfolio pressure

    Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand.

  • Government pricing exposure

    U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.

Primary sources

AbbVie Reports First-Quarter 2026 Financial ResultsAbbVie Inc. · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/29/2026, 12:00:00 AM

Open original source
AbbVie Investor RelationsAbbVie Inc. · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
AbbVie Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source

Continue research

Open risk researchReturn to full stock research